Retinal vascular endothelial growth factor induces intercellular adhesion molecule-1 and endothelial nitric oxide synthase expression and initiates early diabetic retinal leukocyte adhesion in vivo.

Leukocyte adhesion to the diabetic retinal vasculature results in early blood-retinal barrier breakdown, capillary nonperfusion, and endothelial cell injury and death. Previous work has shown that intercellular adhesion molecule-1 (ICAM-1) and CD18 are required for these processes. However the relevant in vivo stimuli for ICAM-1 and CD18 expression in diabetes remain unknown. The current study investigated the causal role of endogenous vascular endothelial growth factor (VEGF) and nitric oxide in initiating these events. Diabetes was induced in Long-Evans rats with streptozotocin, resulting in a two- to threefold increase in retinal leukocyte adhesion. Confirmed diabetic animals were treated with a highly specific VEGF-neutralizing Flt-Fc construct (VEGF TrapA(40)). Retinal ICAM-1 mRNA levels in VEGF TrapA(40)-treated diabetic animals were reduced by 83.5% compared to diabetic controls (n = 5, P < 0.0001). VEGF TrapA(40) also potently suppressed diabetic leukocyte adhesion in retinal arterioles (47%, n = 11, P < 0.0001), venules (36%, n = 11, P < 0.0005), and capillaries (36%, n = 11, P < 0.001). The expression of endothelial nitric oxide synthase (eNOS), a downstream mediator of VEGF activity, was increased in diabetic retina, and was potently suppressed with VEGF TrapA(40) treatment (n = 8, P < 0.005). Further, VEGF TrapA(40) reduced the diabetes-related nitric oxide increases in the retinae of diabetic animals. The inhibition of eNOS with N-omega-nitro-L-arginine methyl ester also potently reduced retinal leukocyte adhesion. Although neutrophil CD11a, CD11b, and CD18 levels were increased in 1-week diabetic animals, VEGF TrapA(40) did not alter the expression of these integrin adhesion molecules. Taken together, these data demonstrate that VEGF induces retinal ICAM-1 and eNOS expression and initiates early diabetic retinal leukocyte adhesion in vivo. The inhibition of VEGF bioactivity may prove useful in the treatment of the early diabetic retinopathy.

[1]  K. Miyarnoto.  Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition , 1999 .

[2]  K Miyamoto,et al.  Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes. , 2000, Investigative ophthalmology & visual science.

[3]  T. Grosser,et al.  NO reduces PMN adhesion to human vascular endothelial cells due to downregulation of ICAM-1 mRNA and surface expression. , 2000, Thrombosis research.

[4]  L. Aiello,et al.  Prevention of leukostasis and vascular leakage in streptozotocin-induced diabetic retinopathy via intercellular adhesion molecule-1 inhibition. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[5]  R. Jain,et al.  During angiogenesis, vascular endothelial growth factor regulate natural killer cell adhesion to tumor endothelium , 1996, Nature Medicine.

[6]  B Kirchhof,et al.  Leukocyte-mediated endothelial cell injury and death in the diabetic retina. , 2001, The American journal of pathology.

[7]  R. Maciewicz,et al.  Treatment with Soluble VEGF Receptor Reduces Disease Severity in Murine Collagen-Induced Arthritis , 2000, Laboratory Investigation.

[8]  H. Ueno,et al.  Experimental subretinal neovascularization is inhibited by adenovirus-mediated soluble VEGF/flt-1 receptor gene transfection: a role of VEGF and possible treatment for SRN in age-related macular degeneration , 2000, Gene Therapy.

[9]  K Miyamoto,et al.  VEGF increases retinal vascular ICAM-1 expression in vivo. , 1999, Investigative ophthalmology & visual science.

[10]  R K Jain,et al.  Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. , 1998, The Journal of investigative dermatology.

[11]  Z. Radisavljevic,et al.  Vascular Endothelial Growth Factor Up-regulates ICAM-1 Expression via the Phosphatidylinositol 3 OH-kinase/AKT/Nitric Oxide Pathway and Modulates Migration of Brain Microvascular Endothelial Cells* , 2000, The Journal of Biological Chemistry.

[12]  K. Nakagawa,et al.  The relation between expression of vascular endothelial growth factor and breakdown of the blood-retinal barrier in diabetic rat retinas. , 1996, Laboratory investigation; a journal of technical methods and pathology.

[13]  D. Lefer,et al.  Enhanced expression of intracellular adhesion molecule-1 and P-selectin in the diabetic human retina and choroid. , 1995, The American journal of pathology.

[14]  S. Kondo,et al.  Vascular endothelial growth factor is induced by long-term high glucose concentration and up-regulated by acute glucose deprivation in cultured bovine retinal pigmented epithelial cells. , 1996, Biochemical and biophysical research communications.

[15]  D. Eliott,et al.  Vascular endothelial growth factor is present in glial cells of the retina and optic nerve of human subjects with nonproliferative diabetic retinopathy. , 1997, Investigative ophthalmology & visual science.

[16]  D. Connolly,et al.  Human mesangial cells and peripheral blood mononuclear cells produce vascular permeability factor. , 1993, Kidney international.

[17]  J. El Benna,et al.  Intracellular pool of vascular endothelial growth factor in human neutrophils. , 1997, Blood.

[18]  S. Rafii,et al.  Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[19]  E S Gragoudas,et al.  Intravitreous injections of vascular endothelial growth factor produce retinal ischemia and microangiopathy in an adult primate. , 1996, Ophthalmology.

[20]  M. Lauritzen,et al.  Nitric Oxide Synthase Activity and Expression in Experimental Diabetic Neuropathy , 2000, Journal of neuropathology and experimental neurology.

[21]  G. Schmid-Schönbein,et al.  Activated monocytes and granulocytes, capillary nonperfusion, and neovascularization in diabetic retinopathy. , 1991, The American journal of pathology.

[22]  J. Cunha-Vaz,et al.  Nitric oxide synthase activity in retinas from non-insulin-dependent diabetic Goto-Kakizaki rats: correlation with blood-retinal barrier permeability. , 2000, Nitric oxide : biology and chemistry.

[23]  T. Horiuchi,et al.  Expression of vascular endothelial growth factor by human eosinophils: upregulation by granulocyte macrophage colony-stimulating factor and interleukin-5. , 1997, American journal of respiratory cell and molecular biology.

[24]  Peitan Liu,et al.  NO modulates P-selectin and ICAM-1 mRNA expression and hemodynamic alterations in hepatic I/R. , 1998, American journal of physiology. Heart and circulatory physiology.

[25]  D. Connolly,et al.  Vascular permeability factor: a tumor-derived polypeptide that induces endothelial cell and monocyte procoagulant activity, and promotes monocyte migration , 1990, The Journal of experimental medicine.

[26]  K Miyamoto,et al.  Vascular endothelial growth factor (VEGF)-induced retinal vascular permeability is mediated by intercellular adhesion molecule-1 (ICAM-1). , 2000, The American journal of pathology.

[27]  S. Soker,et al.  Peripheral blood T lymphocytes and lymphocytes infiltrating human cancers express vascular endothelial growth factor: a potential role for T cells in angiogenesis. , 1995, Cancer research.